Company: INKT
Filing Date: 2025-11-07
Form Type: S-3
Source: 0001193125-25-272532
Chunk: 11

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-11-07
Form: S-3
Chunk 11
---
 to progress additional programs to create a clinical 
 portfolio;                                                                                                    |

| • |     | the implementation of our strategic plans for our business, programs, product candidates and technology; |

| • |     | the scope of protection we are able to establish and maintain for intellectual property rights covering our 
 product candidates and technology;                                                                          |

| • |     | developments related to our competitors and our industry; |

| • |     | our ability to maintain our collaborative relationship with Agenus Inc., as well as our ability to identify and 
 enter into future license agreements and collaborations;                                                        |

| • |     | regulatory developments in the United States and foreign countries; |

| • |     | our ability to attract and retain key scientific and management personnel; and |

| • |     | our estimates of our expenses, capital requirements and needs for additional financing. |

The forward-looking statements included in this prospectus are made only as of the date hereof. You should not rely upon forward-looking statements as predictions of future events. We cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Except as required by applicable law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this prospectus to conform these statements to actual results or to changes in our expectations. 6

You should read this prospectus, any prospectus supplement and the documents that we
incorporate by reference herein and therein completely and with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.

7

USE OF PROCEEDS

Except as otherwise provided in the applicable prospectus supplement relating to a specific offering, we intend to use the net proceeds from
the sale of securities by us under this prospectus for working capital and other general corporate purposes. General corporate purposes may include, without limitation, research and development expenditures, preclinical and clinical development and
commercialization of our product candidates, the acquisition or in-licensing of products or product candidates, business or technologies, collaborations, working capital and capital expenditures. We may
temporarily invest the net proceeds we receive in short-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government and its agencies.

We have not determined the amount of net proceeds to be used specifically for such purposes. As a result, management will have broad
discretion in the application